Global API Market Undergoes Structural Transformation: High-Value-Added Products Emerge as New Growth Engine

The global Active Pharmaceutical Ingredients (API) market is undergoing a critical transformation from "scale expansion" to "value enhancement".

The global API market reached $23.87 billion in 2024.

It is projected to grow to $42.85 billion by 2033, representing a compound annual growth rate (CAGR) of approximately 6.8%.

Market growth is driven by both generic drug expansion from patent cliffs and global supply chain restructuring.

High-complexity, high-value-added specialty APIs have become the new focus of industry competition.

1. Regional Market Divergence Intensifies, Global Supply Chain Resilience Tested

1.1 Europe's Traditional API Hub Status Challenged, Production Accelerates Eastward

Europe, the traditional center for complex API and regulated market supply, faces severe industrial challenges.

Global generic drug giant Teva Pharmaceuticals announced the sale of its API business in February 2024, valued at approximately $2 billion.

As of April 2025, no buyer has been found for the asset.

High energy costs driven by geopolitical conflicts have further accelerated the transfer of some key antibiotic raw material production to Asia.

1.2 India's API Market Grows Strongly, Heavily Dependent on China for KSM

India's API market demonstrates robust growth momentum.

India's API market size reached $14.7 billion in 2025.

It is expected to grow to $22 billion by 2030.

India has promoted the localization of 53 APIs through its Production-Linked Incentive (PLI) scheme.

However, 68.8% of its Key Starting Materials (KSM) still rely on imports from China.

2. Procurement Logic Shifts Fundamentally, Demand for High-Barrier Products Surges

2.1 Procurement Decisions Turn Risk-Oriented, Global Regional Division of Labor Reshaped

The global pharmaceutical supply chain presents distinct new characteristics in 2025.

Buyer decisions are shifting from pure cost orientation to risk-adjusted comprehensive assessments.

Dual-sourcing and nearshoring strategies are becoming increasingly prevalent.

The global API industry's regional division of labor has become clearer:

• Europe focuses on complex API R&D and production
• China and India remain the primary suppliers of APIs and intermediates
• Southeast Asia and the Middle East emerge as secondary centers for finished dosage forms

2.2 Market Demand Migrates to High-Value Segments, Peptide APIs Become Core Track

The "value migration" trend in the global API market is particularly pronounced.

Innovative therapies in oncology, metabolic diseases, and cardiovascular fields drive strong demand for high-end specialty APIs.

Within this, peptide APIs related to GLP-1 receptor agonists have seen continuous increases in technical barriers and market value.

The following are typical representatives of current high-barrier, high-value-added peptide APIs:

• Metabolic diseases: Cagrilintide (CAS: 1415456-99-3), Tirzepatide (CAS: 2023788-19-2), Retatrutide (CAS: 2381089-83-2)
• Gastrointestinal diseases: Linaclotide (CAS: 851199-59-2), Plecanatide (CAS: 467426-54-6)
• Antithrombotic therapy: Eptifibatide (CAS: 188627-80-7)

Their complex synthesis routes and strict quality control standards make their production capacity and supply stability a top concern for downstream formulation companies.

3. Global Regulatory Cooperation Strengthens, Driving Industry Compliance Upgrades

Global regulatory agencies are actively adapting to the structural changes in the API industry.

The U.S. FDA updated its API Process Inspections guidance in August 2025, incorporating more comprehensive quality risk management principles.

The European Medicines Agency (EMA) has issued a new reflection paper on non-mutagenic impurity control.

The International Coalition of Medicines Regulatory Authorities (ICMRA) successfully piloted hybrid inspections (on-site + remote).

China is accelerating its integration into the PIC/S international inspection mutual recognition network.

These developments pave the way for the global compliance and efficient circulation of complex APIs.

4. Future Outlook: Technical Capabilities Will Become Core Competitive Advantage

The period from 2025 to 2037 will see a massive window of concentrated patent expirations for originator drugs.

Over $200 billion in originator drug sales will face patent cliffs during this period.

The expansion of generic drugs will bring deterministic growth to specialty APIs.

The true market winners will be companies that can overcome synthetic technical challenges, meet stringent global regulatory requirements, and stably supply high-value-added APIs such as peptides.

Competition in the global API market has officially entered an advanced stage centered on technical strength and quality management systems.

Information Sources

1. DataM Intelligence Global API Market Report 2025
2. Mordor Intelligence India API Market Analysis Report 2025
3. U.S. FDA Official API Process Inspections Guidance (CPGM 7356.002F), August 2025
4. European Medicines Agency (EMA) Reflection Paper on the Definition of Non-Mutagenic Impurities, February 2026
5. International Coalition of Medicines Regulatory Authorities (ICMRA) Collaborative Hybrid Inspection Pilot Summary Report, March 2025
6. Evaluate Pharma Global Originator Drug Patent Expiration Forecast 2025-2037
7. Teva Pharmaceuticals Official Announcement, January 31, 2024

Disclaimer

This article is for industry information exchange and reference only. It does not constitute any investment advice, medical advice, or business decision-making basis. The data and views presented herein are derived from publicly available authoritative sources, but we make no express or implied warranties regarding their accuracy, completeness, or timeliness. Any decisions made by readers based on this information are at their own risk.